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Aims Several clinical trials have shown that in patients with acute myocardial infarction (MI), statin therapy improves
cardiovascular (CV) outcomes, but in these trials patients with acute heart failure (HF) were excluded or only a
few were included. In patients with chronic HF, statin therapy does not reduce all-cause or CV mortality. We
aimed to assess the association between statin therapy and clinical outcomes in the setting of acute HF with systolic
dysfunction complicating acute MI.
Methods
and results
We performed a post-hoc analysis in 6632 patients included in the EPHESUS trial. The mean age of patients was 64
years and 71% were male. Overall, 47% of patients had a statin prescribed at baseline. Cox regression models and a
secondary analysis using propensity score matching were fit to assess the association between statin prescription and
clinical outcomes. During a mean follow-up of 16+7 months, all-cause death occurred in 385 (12%) patients with
and in 647 (18%) patients without a statin (P , 0.001). After extensive adjustment, the risk of all-cause death was 20%
lower in patients on statin [hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.69–0.92, P ¼ 0.001]. This positive
association was mostly due to a lower risk of CV death (HR 0.76, 95% CI 0.65–0.88, P ¼ 0.0002). In contrast, statin
use was associated with a higher risk of non-CV hospitalizations (HR 1.16, 95% CI 1.02–1.33, P ¼ 0.02).
Conclusion Our results suggest that patients with acute HF complicating acute MI may benefit from being on statin therapy.
Prospective clinical trials are required to validate these findings.
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Introduction
Several clinical trials have shown that in acute and post-acute myo-
cardial infarction (MI) statin therapy improves cardiovascular (CV)
morbidity and mortality as well as all-cause mortality.1 – 4 Based on
this evidence, statin treatment is a cornerstone therapy in patients
with acute and post-acute coronary artery disease (CAD) and in
patients at high risk of developing CAD. However, in previous
trials of acute and post-acute MI, patients with acute heart
failure (HF) were excluded or only a few were included.428
Thus, the effect of statin therapy in this particular subgroup of
patients is not clearly established.
Patients with chronic heart failure (CHF) frequently have a
history of CAD as well as a pathophysiology of inflammation, fibro-
sis, and hypertrophy.9 Thus, it was hypothesized and also suggested
by retrospective analysis of major clinical trials that statin
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treatment may also have a prognostic benefit in patients with
established CHF.10,11 However, the prospective CORONA as
well as GISSI-HF trials have shown that treatment with rosuvastatin
does not reduce all-cause mortality in patients with systolic CHF,
although the drug did reduce the number of CV hospitalizations
in the CORONA trial.12,13 However, these trials did not investigate
whether patients who evolve to CHF while receiveing a statin
benefit from the therapy. Thus, whether statin therapy may
exert a protective effect when prescribed at initial stages of HF
development is an important and unsolved clinical question.
The EPHESUS (Eplerenone Post-Acute Myocardial Infarction
Heart Failure Efficacy and Survival study) trial assessed the
effects of the mineralocorticoid receptor antagonist eplerenone
in patients with acute MI complicated by clinical signs and symp-
toms of HF and left ventricular dysfunction.14 About half of the
patients had a statin prescribed at baseline. In this study, we
aimed to assess the association between statin prescription at
baseline and clinical outcomes in patients with acute systolic HF
included in the EPHESUS trial.
Methods
The study design and results of the EPHESUS trial have been published
previously.14,15 In brief, EPHESUS was a multicentre, randomized,
double-blind trial including 6632 patients with acute MI complicated
by clinical signs and symptoms of HF and a left ventricular ejection frac-
tion (LVEF) ≤ 40%. In patients with diabetes who met the criteria of
left ventricular dysfunction after acute MI, clinical signs and symptoms
of HF did not have to be demonstrated. Eligible patients were rando-
mized to either treatment with eplerenone (n ¼ 3319) or placebo
(n ¼ 3313) between 3 and 14 days after acute MI, and were followed
for up to 33 months (mean follow-up 16 months).
We performed a post-hoc analysis in all 6632 patients included in
the EPHESUS trial. We assessed the association between statin pre-
scription at baseline and clinical outcomes. The baseline represented
the entire period of hospital stay, including the period before and
after randomization to eplerenone, and hospital discharge. There
were missing values at baseline for a few clinical variables used for ad-
justment; therefore, the final multivariate Cox analysis was performed
in 6213 patients.
Outcomes
We assessed the association between statin prescription at baseline
and all clinical outcomes measured in the EPHESUS trial. This includes
the two primary outcomes [all-cause death, and the combined
outcome of CV death or first CV hospitalization (including HF, recur-
rent MI, stroke, and ventricular arrhythmia hospitalization]. The sec-
ondary outcomes were CV death, and all components of CV death,
including sudden death. Further, we assessed the impact of statin use
on CV and non-CV hospitalizations. All outcomes were adjudicated
by the blinded critical event committee and hard recorded in the
database.
Statistical methods
At baseline, continuous variables were described as means+ standard
deviation (SD), and categorical variables as frequencies (percentages).
Variables were compared by using a t-test or a x2 test, as required.
We assessed the association between baseline statin prescription
and clinical outcomes using a multivariate Cox proportional hazard re-
gression models. We adjusted for the significantly different baseline
variables and those considered clinically important. The following vari-
ables were tested in the final multivariate model for primary and sec-
ondary outcomes: age, gender, race, smoking status, body mass index
(BMI), total cholesterol, mean arterial pressure, LVEF, estimated glom-
erular filtration rate (eGFR), reperfusion or revascularization, history
of angina, MI, hypertension, diabetes, previous HF hospitalization,
and concomitant medication with angiotensin-converting enzyme inhi-
bitors (ACEIs) or angiotensin receptor blockers (ARBs), beta-blockers,
other lipid-lowering drugs, aspirin, other antiplatelet agents, anticoagu-
lants, antiarrhythmics, diuretics, and the study drug.
We checked the log-linearity of the continuous variables and the
Cox proportionality assumptions of all variables. The log-linearity
was assessed by generating one dummy variable per quintile of each
variable, entering these in the Cox model, and plotting the resulting
Cox estimators against the mean values of the quintiles. Based on
the log-linearity criteria, we reclassified the continuous variables ejec-
tion fraction and heart rate from continuous to categorical variables
(EF .35% and HR .80 b.p.m.). Assumption of risk proportionality
was assessed statistically by testing the cofactor × time interaction
and visually by plotting the log[– log(survival)] curves.
We also checked the model for multicollinearity, and, because we
found a high correlation between total cholesterol and LDL choles-
terol (r ¼ 0.5), we included in the final model only total cholesterol.
We excluded HDL from the final model because 635 patients had
missing values on this variable.
We checked for interactions between statin use and all significant
variables from the final model—age, ejection fraction, GFR, angina,
previous MI, diabetes, revascularization, stroke, beta-blocker, anti-
coagulant, and antiplatelet agents, and none was significant (P , 0.05).
All analyses were performed using SAS version 9.2 (SAS Institute
Inc., Cary, NC, USA). Results were estimated as hazard ratios (HRs)
with 95% confidence intervals (CIs). The two-tailed significance level
was set at P , 0.05.
Sensitivity analysis:propensity score analysis
(pseudo-randomization)
A secondary analysis using propensity score matching was performed
to validate the findings of the Cox analysis. Propensity scores were
constructed using logistic regression with statin use as predicted
event and baseline covariates as predictors. All variables shown in
Table 1 were used as covariates. The efficacy of propensity score
matching (covariant balance) was assessed by evaluating the standard
difference in covariates between patients with and without a statin.
The standard difference measures the degree of bias in covariate
means across exposure. All Cox analyses were performed on the
subsample of propensity score-matched patients.
Results
Overall, 3095 patients (47%) had a statin prescribed at baseline.
From the 47% of patients who had a statin at baseline,  10%
had a statin prescribed before hospital admission for acute MI,
and 90% had a statin initiated during hospital stay. Patient charac-
teristics at baseline are presented in Table 1. The mean age of the
patients was 64+ 11 years and 71% were male. Patients who
received a statin prescription were younger, more often
smokers, and had a higher BMI, a lower LVEF, but a better
kidney function on average. Furthermore, they had a higher total
cholesterol level and more frequently a history of reperfusion or
revascularization. Patients on statins also had a higher prescription
D. Dobre et al.222
rate of most HF classes of medication, except for anticoagulants,
other lipid-lowering drugs, antiarrhythmics, and diuretics, which
were more often prescribed in patients without a statin.
Univariate Cox survival analysis
During a mean follow-up of 16+ 7 months, all-cause death
occurred in 385 (12%) patients with and in 647 (18%) patients
without a statin (Table 2). Death from CV causes accounted for
the majority of all-cause death events in both statin and non-statin
patients (326 events, 85% in the statin group; and 564 events, 87%
in the non-statin group). Sudden death accounted for the majority
of deaths from CV causes (40%).
In univariate survival analysis, the risk of all-cause death was 34%
lower in statin vs. non-statin users (HR 0.66, 95% CI 0.59–0.75,
P , 0.001). Kaplan–Meier survival curves clearly show a benefit
of statin use on all-cause death, with the two curves differentiating
immediately after baseline (Figure 1).
Statin prescription was also univariately associated with a
significant benefit on the composite outcome of CV death or
CV hospitalization (HR 0.86, 95% CI 0.78–0.94, P , 0.001), on
CV death (HR 0.65, 95% CI 0.56–0.74; P , 0.001), and on all
causes of CV death (Table 2).
Further, statin use was associated with a lower risk for a first
hospitalization for non-fatal stroke as well as both fatal and
non-fatal stroke (Tables 2 and 3).
In contrast, statin use was associated with a small increase in the
composite outcome of all-cause death or all-cause hospitalization
(HR 1.08, 95% CI 1.01–1.15, P ¼ 0.02) (Table 2). When we
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Table 1 Baseline characteristics of patients according to statin use
Characteristics Statin (n 5 3095) No statin (n 5 3537) P-value
General characteristics
Age, years, mean (SD) 62.2+11.6 65.4+11.2 ,0.001
Female sex, n (%) 820 (26.5) 1098 (31.0) ,0.001
Race, n (%) 0.004
Caucasian 2779 (89.8) 3205 (90.6)
Black 44 (1.4) 30 (0.8)
Other 33 (1.1) 35 (1)
Clinical presentation
Smoking, n (%) 2075 (67) 1965 (56) ,0.001
Body mass index, kg/m2 27.7+4.6 27.1+4.4 ,0.001
Total cholesterol, mg/dL 5.1+1.3 4.9+1.3 ,0.001
LDL cholesterol, mg/dL 3.0+1.1 3.3+1.5 0.1
HDL cholesterol, mg/dL 1.1+2.4 1.2+2.9 0.3
Heart rate .80 b.p.m., n (%) 1046 (33.8) 1190 (33.7) 0.8
MAP, mean (SD) 86.2+11.2 89.1+11.4 ,0.001
LVEF .35%, n (%) 1650 (53.5) 1996 (56.5) ,0.001
eGFR, mL/min/1.73 m2, mean (SD) 71.8+21.5 68.2+21.5 ,0.001
Reperfusion or revascularization, n (%) 1764 (57) 1242 (35) ,0.001
Clinical history, n (%)
Angina pectoris 1203 (38.9) 1532 (43.3) ,0.001
Myocardial infarction 871 (28.1) 932 (26.4) 0.1
Hypertension 1771 (57.2) 2236 (63.2) ,0.001
Diabetes 1034 (33.4) 1108 (31.3) 0.07
Atrial fibrillation or flutter 80 (2.6) 107 (3.0) 0.3
Previous hospitalization for HF 219 (7.1) 293 (8.2) 0.06
Medications, n (%)
Other lipid-lowering drugs 38 (1.2) 69 (1.9) 0.02
ACE inhibitor or angiotensin receptor blocker 2806 (90.7) 2945 (83.3) ,0.001
Beta-blockers 2495 (80.6) 2466 (69.7) ,0.001
Aspirin 2786 (90.0) 3084 (87.2) ,0.001
Other antiplatelet agents 1277 (41.3) 633 (17.9) ,0.001
Anticoagulant 424 (13.7) 684 (19.3) ,0.001
Antiarrhythmic 307 (9.9) 475 (13.4) ,0.001
Diuretics 1754 (56.7) 2230 (63.1) ,0.001
Eplerenone 1550 (50.1) 1679 (50.0) 0.9
ACE, angiotensin-converting enzyme; eGFR, estimated glomerular filtration rate; HF, heart failure; LVEF, left ventricular ejection faction; MAP, mean arterial pressure.
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assessed individually the cause of hospitalization, we found no
significant association with the risk of CV hospitalizations, but a
significant association with the risk of non-CV hospitalizations
(HR 1.20, 95% CI 1.06–1.36, P ¼ 0.004) (Table 3).
Multivariate Cox analysis
After extensive adjustment, the risk of all-cause death remained
20% lower in patients with vs. those without a statin (HR 0.80,
95% CI 0.69–0.92, P ¼ 0.001) (Table 2). This positive association
was mostly due to a lower risk of CV death (HR 0.76, 95% CI
0.65–0.88, P ¼ 0.0002). The reduction of CV death was mainly
due to a lower rate of sudden death (HR 0.77, 95% CI 0.61–
0.96, P ¼ 0.02) and death from stroke (HR 0.53, 95% CI 0.28–
0.96, P ¼ 0.04), but was also due a lower rate of death from
worsening HF and from recurrent acute MI (Table 2).
After adjustment, statin use was not associated with a positive
effect on the composite outcome of CV death or CV hospitaliza-
tion; this was probably due to a non-significant effect on non-fatal
CV hospitalizations (Table 2).
Statin use was not associated with the overall risk of a first (fatal
and non-fatal) CV hospitalization, or a first hospitalization for HF,
but appeared to be associated with a lower risk of hospitalization
for stroke (HR 0.72, 95% CI 0.51–1.00, P ¼ 0.05) (Table 3). In con-
trast, statin use remained associated with a higher risk of non-CV
hospitalizations (HR 1.16, 95% CI 1.02–1.33, P ¼ 0.02) (Table 3).
Propensity score analysis
After matching, 4322 patients were subdivided into statin and no
statin intake groups. The Cox analysis performed in this subsample
of patients showed results similar to those obtained in the multi-
variate Cox model performed in the full sample of patients. This
included: (i) a small increase in the risk of all-cause death or hos-
pitalization (HR 1.14, 95% CI 1.05–1.23, P ¼ 0.002); and (ii) an in-
crease in non-CV hospitalizations (HR 1.17, 95% CI 1.01–1.35,
P ¼0.04) in statin users vs. non-statin users (Table 4).
Discussion
In this post-hoc analysis of the EPHESUS trial, we found that initi-
ation of statin therapy mainly during hospital stay for acute HF
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Table 2 The association between statin prescription and clinical outcomes in univariate and multivariate Cox analysis
Outcome Statin, n (%)
(n 5 3095)
No statin, n
(%) (n 5 3537)
Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Primary
All cause death 385 (12%) 647 (18%) 0.66 (0.59–0.75) ,0.001 0.80 (0.69–0.92) 0.001
CV death or CV hospitalization 813 (26%) 1065 (30%) 0.86 (0.78–0.94) 0.0008 0.97 (0.88–1.06) 0.3
Secondary
All-cause death or hospitalization 1703 (55%) 1856 (52%) 1.08 (1.01–1.15) 0.02 1.09 (1.01–1.17) 0.02
CV death 326 (11%) 564 (16%) 0.65 (0.56–0.74) ,0.001 0.76 (0.65–0.88) 0.0002
Sudden death (CV) 135 (4%) 228 (6%) 0.66 (0.53–0.82) 0.0001 0.77 (0.61–0.96) 0.02
Death from acute MI 63 (2.04) 109 (3.08) 0.65 (0.48–0.89) 0.006 0.74 (0.54–1.02) 0.07
Death from worsening HF 86 (2.8) 145 (4.1) 0.66 (0.51–0.86) 0.002 0.75 (0.56–1.01) 0.06
Death from stroke 15 (0.5) 39 (1.1) 0.43 (0.24–0.77) 0.005 0.53 (0.28–0.96) 0.04
CV hospitalizations (non-fatal)
CV hospitalizations overall 589 (19%) 666 (18.8%) 0.9 (0.88–1.1) 0.9 – –
Myocardial infarction 230 (6.5%) 223 (7.2) 1.09 (0.90–1.30) 0.4 – –
Heart failure 341 (11%) 395 (11.2%) 0.97 (0.84–1.12) 0.6 – –
Ventricular arrhythmias 53 (1.7) 53 (1.5) 1.12 (0.77–1.64) 0.5 – –
Stroke 46 (1.5) 75 (2.1) 0.68 (0.47–0.99) 0.04 0.81 (0.56–1.19) 0.3
CI, confidence interval; CV, cardiovascular; HR, hazard ratio; MI, myocardial infarction.
Figure 1 Kaplan-Meier survival curves (all-cause death) in
patients who receive or not a statin at baseline.
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complicating acute MI is associated with a lower risk of all-cause
death. This positive association was mostly due to a reduction in
CV death. Statin use was not significantly associated with the
overall risk of CV hospitalization, including HF and MI, but was
associated with a lower risk of stroke hospitalization. In contrast,
statin use was associated with a moderately higher rate of
non-CV hospitalizations.
While statin therapy has been shown to have a benefit in a
broad range of patients with acute and post-acute CAD, its
benefit in the subgroup of patients with acute systolic HF compli-
cating acute MI has not been specifically studied. Only 8% of
patients with HF were enrolled in the MIRACL trial (patients
with unstable angina and non-Q-wave acute MI),4 and only 6% of
them were enrolled in the IDEAL trial (post-acute MI patients).8
In the PROVE-IT trial (acute MI or high-risk unstable angina), the
proportion of HF patients included is not clear, but at the time
of enrolment patients had to be in a stable condition.5 Further-
more, in trials enrolling patients undergoing angioplasty or
cardiac surgery, only 4% of patients had HF.6,7 Our positive findings
in acute HF patients are in contrast to findings reported in CHF
patients. Indeed, in both CORONA12 and GISSI-HF trials,13 treat-
ment with rosuvastatin did not reduce all-cause or CV mortality.
There are a number of differences between our study and the
previous CHF trials that may explain the different findings. The
CORONA trial included elderly patients, with a mean age of 73
years, while the EPHESUS trial included patients 10 years
younger, i.e. mean age 64 years. In the elderly HF population, an
effect on all-cause death is difficult to achieve with any drug
given the age competitive factor.16,17 On the other hand, it may
very well be that the pathophysiology of the disease is different
in CHF compared with initial disease stages. Several studies have
shown that while high cholesterol levels are associated with
higher risk in patients with CAD,18 they seem to be protective
in established CHF,19 and in the elderly population in general.20
This phenomenon of ‘reverse epidemiology’ in CHF has also
been observed with regard to BMI.21 Nevertheless, the concept
of ‘reverse epidemiology’ was refuted several times given the con-
founding factor of the underlying sickness of CHF patients.
However, it seems rather that the first hypothesis is more plausible
as in the CORONA trial rosuvastatin did reduce the number of CV
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Table 3 The association between statin prescription and the first cardiovascular and non-cardiovascular hospitalization
(fatal and non-fatal)
Outcome Statin,
n (%) (n 5 3095)
No statin,
n (%) (n 5 3537)
Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
CV hospitalization overall 651 (21.3%) 777 (22%) 0.97 (0.89–1.63) 0.5 – –
Heart failure 378 (12.2%) 453 (12.8%) 0.94 (0.82–1.07) 0.4 – –
Acute MI 252 (7.9%) 281 (8.1%) 1.00 (0.85–1.19) 0.9 – –
Ventricular arrhythmias 53 (1.7) 53 (1.5) 1.12 (0.77- 1.64) 0.5 – –
Unstable angina 302 (9.8) 326 (9.2) 1.0 (0.89–1.2) 0.7 – –
Stable angina 89 (2.9) 87 (2.5) 1.14 (0.85–1.53) 0.4 – –
Stroke 56 (1.8) 105 (3) 0.59 (0.43–0.82) 0.002 0.72 (0.51–1.00) 0.05
Non-CV hospitalizations 550 (17.8 %) 527 (14.9) 1.20 (1.06–1.36) 0.004 1.16 (1.02–1.33) 0.02
CI, confidence interval; CV, cardiovascular; HR, hazard ratio; MI, myocardial infarction.
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Table 4 The association between statin prescription and clinical outcomes in propensity score analysis




No statin, n (%)
(n 5 2161)
Cox analysis
HR (95% CI) P-value
All-cause death 639 (15) 292 (46) 347 (54) 0.84 (0.72–0.98) 0.03
CV death or CV hospitalization 1255 (29) 628 (50) 627 (50) 1.01 (0.90–1.13) 0.87
All-cause death or hospitalization 2364 (54.7) 1228 (52) 1136 (48) 1.14 (1.05–1.23) 0.002
CV death 549 (13) 248 (45) 301 (55) 0.82 (0.69–0.97) 0.02
CV hospitalizations (fatal and non-fatal) 1314 (30) 664 (51) 650 (49) 1.03 (0.92–1.15) 0.62
Non CV hospitalizations (fatal and
non-fatal)
724 (17) 388 (54) 336 (46) 1.17 (1.01–1.35) 0.04
CI, confidence interval; CV, cardiovascular; HR, hazard ratio.
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hospitalizations.12 Interestingly, in the GISSI-HF trial, prescription
of rosuvastatin was not associated with any clinical benefit.13 In
this trial, however, only 40% of patients had a history of ischaemic
disease and 33% an acute MI, as opposed to 60% and 100% of
patients with an acute MI in the CORONA and the EPHESUS
trial, respectively. From the perspective of these trials, one may
speculate that statin therapy could be more beneficial in ischae-
mic/post- acute MI HF patients. Nevertheless, more prospective
studies are necessary to confirm this hypothesis.
Statin therapy may have beneficial effects in patients with acute
HF not only by lowering cholesterol, but also by a plethora of
pleiotropic effects, including reduction of inflammation and im-
provement of endothelial function,22– 24 as well as by a protective
effect on renal function.25 The lack of a significant effect of statin
use on the first CV hospitalization observed in our study is difficult
to interpret, and could probably be explained by the fact that by
living longer, patients on statin therapy have a higher chance of
being hospitalized. However, we found a borderline beneficial
effect on stroke hospitalization, and also a considerable reduction
in the risk of death from stroke with statin use (50% risk reduc-
tion). Given the positive effects of statins on vascular function
and capillary density,26,27 one would expect a reduction of
stroke events, but also a more pronounced effect on recurrent
acute MI or worsening HF events. Whether this lower effect on
acute MI/HF hospitalizations is due to specific HF disease charac-
teristics or due to adverse effects of statins on ubiquinone (coen-
zyme Q10) production, which may affect cardiac metabolism,28,29
or both, has to be further explored.
In contrast to the beneficial or neutral effects of statin use on
CV death and CV hospitalizations, we found a higher risk with
drug use on the combined outcome of all-cause death or hospita-
lizations, which was mostly attributable to non-CV hospitalizations.
Although this effect may be a chance finding, it remained significant
in various models, including propensity score analysis. One may
speculate that by living longer, patients on statin are at higher
risk for non-CV hospitalizations. However, this does appear to
be the case for CV hospitalizations. Our database did not allow
a detailed analysis of the cause of non-CV hospitalizations as
these events have not been adjudicated by an expert committee
in the EPHESUS trial. However, previous meta-analyses have
pointed out that statin therapy may be associated with adverse
events, such as myopathy, new-onset diabetes, and an increase in
hepatic enzymes.30232 The risk of adverse events may be particu-
larly elevated with high doses of statins, but unfortunately we do
not have data on the dose of statin prescribed in this study.
There are several strengths and limitations of our study. The
study was performed in a very large trial database of acute
post-MI acute HF patients. This very large number of patients
(6300 patients) and events (1032 death events) are usually seen
in meta-analytic studies. The main limitation is the post-hoc
nature of the study, i.e. patients were not prospectively rando-
mized to statin or placebo. To address the issue of confounding
by indication, we applied two different statistical methods which
showed similar results. First, we adjusted for an extensive
number of clinical variables (23 clinical covariates) in a multivariate
Cox model, and, secondly, we performed a matched propensity
score analysis. However, there may be unknown or unmeasured
confounding variables which were not adjusted for, and which
could have affected some or all of the observed relationships.
This bias may apply especially for non-CV hospitalizations as
adjusting for all possible risk factors is particularly difficult in a
post-hoc analysis. Secondly, we assumed that patients who did
not initiate statin therapy during hospitalization will not initiate it
during follow-up, and those who initiated the therapy at baseline
would not stop it. Previous studies have shown that patients dis-
charged without a drug prescription are unlikely to be started
on these therapies as outpatients.33,34 Indeed, in our study, 70%
of patients on a statin at baseline were still taking a statin at the
last visit, and in patients not on a statin at baseline, 18% were
taking a statin at the last visit, and as such we assume that the
effect size did not change to a great extent.
In conclusion, in patients with acute HF post-MI, statin therapy
was associated with a lower risk of all-cause death. The reduction
of all-cause death appears to be mainly attributable to a lower rate
of CV death, especially sudden death and stroke. Prospective clin-
ical trials are required to validate these findings.
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